JPWO2019231920A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019231920A5
JPWO2019231920A5 JP2020566664A JP2020566664A JPWO2019231920A5 JP WO2019231920 A5 JPWO2019231920 A5 JP WO2019231920A5 JP 2020566664 A JP2020566664 A JP 2020566664A JP 2020566664 A JP2020566664 A JP 2020566664A JP WO2019231920 A5 JPWO2019231920 A5 JP WO2019231920A5
Authority
JP
Japan
Prior art keywords
chain variable
seq
amino acid
variable domain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525731A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034186 external-priority patent/WO2019231920A1/en
Publication of JP2021525731A publication Critical patent/JP2021525731A/ja
Publication of JPWO2019231920A5 publication Critical patent/JPWO2019231920A5/ja
Priority to JP2023201568A priority Critical patent/JP7726967B2/ja
Pending legal-status Critical Current

Links

JP2020566664A 2018-05-28 2019-05-28 多重特異性結合タンパク質及びその改善 Pending JP2021525731A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023201568A JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677137P 2018-05-28 2018-05-28
US62/677,137 2018-05-28
PCT/US2019/034186 WO2019231920A1 (en) 2018-05-28 2019-05-28 Multi-specific binding proteins and improvements thereon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023201568A Division JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Publications (2)

Publication Number Publication Date
JP2021525731A JP2021525731A (ja) 2021-09-27
JPWO2019231920A5 true JPWO2019231920A5 (enExample) 2022-06-07

Family

ID=68697331

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566664A Pending JP2021525731A (ja) 2018-05-28 2019-05-28 多重特異性結合タンパク質及びその改善
JP2023201568A Active JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023201568A Active JP7726967B2 (ja) 2018-05-28 2023-11-29 多重特異性結合タンパク質及びその改善

Country Status (15)

Country Link
US (1) US20210214436A1 (enExample)
EP (2) EP3802581A4 (enExample)
JP (2) JP2021525731A (enExample)
KR (1) KR20210013160A (enExample)
CN (2) CN112533944A (enExample)
AU (1) AU2019277138B2 (enExample)
BR (1) BR112020024235A2 (enExample)
CA (1) CA3101604A1 (enExample)
CL (1) CL2020003071A1 (enExample)
EA (2) EA202091977A1 (enExample)
IL (1) IL278943A (enExample)
MX (1) MX2020012905A (enExample)
PE (1) PE20210167A1 (enExample)
SG (1) SG11202011763YA (enExample)
WO (1) WO2019231920A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3214521A1 (en) * 2015-03-10 2016-09-15 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス, インコーポレイテッド Her2、NKG2DおよびCD16に結合するタンパク質
LT3652215T (lt) 2017-07-14 2021-05-25 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
JP7353576B2 (ja) * 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス, インコーポレイテッド Cd33、nkg2d、及びcd16に結合する多重特異性結合タンパク質、ならびにその使用方法
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
JP2021534096A (ja) * 2018-08-08 2021-12-09 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16および腫瘍関連抗原に結合するタンパク質
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
WO2020148372A1 (en) * 2019-01-17 2020-07-23 Immunocore Limited Formulations
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
WO2021220215A1 (en) * 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
AR122018A1 (es) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y clec12a
CN116368154A (zh) * 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
US20240034795A1 (en) * 2020-12-31 2024-02-01 Innovent Biologics (Suzhou) Co., Ltd. Protein containing heterodimer antibody fc, and preparation method therefor
EP4271714A4 (en) * 2021-01-11 2025-06-25 Adimab, LLC MODIFIED VARIANT CH3 DOMAINS FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THEM, AND METHODS OF MAKING THEM
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
TW202304992A (zh) * 2021-03-31 2023-02-01 美商健生生物科技公司 用於免疫效應細胞重導向的材料及方法
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
EP4405398A4 (en) * 2021-09-21 2025-10-29 Qilu Puget Sound Biotherapeutics Corp FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
WO2025011471A1 (en) * 2023-07-07 2025-01-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Egfr/c-met bispecific binding protein and use thereof
WO2025050020A1 (en) * 2023-08-30 2025-03-06 Mink Therapeutics, Inc. Novel t cell receptors that bind to preferentially expressed antigen in melanoma (prame) and methods of use thereof
WO2025233431A1 (en) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
MX2007003910A (es) * 2004-10-01 2007-06-07 Avidex Ltd Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
KR101615935B1 (ko) 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 nkg2d에 대한 항체 및 그것의 용도
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SI2794658T1 (sl) * 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
JP6571527B2 (ja) * 2012-11-21 2019-09-04 ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. 二重特異性抗体
CN104955953B (zh) * 2012-11-27 2019-04-26 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对,其制备方法及用途
WO2014145806A2 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
WO2016087416A1 (en) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US20160176983A1 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
AU2016206707A1 (en) * 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
EP3095792A1 (en) * 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
DK3313876T3 (da) * 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
WO2017081190A1 (en) * 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス,インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
EP3579848B1 (en) * 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907253VA (en) * 2017-02-10 2019-09-27 Dragonfly Therapeutics Inc Proteins binding bcma, nkg2d and cd16
JP7685821B2 (ja) * 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス, インコーポレイテッド Her2、NKG2DおよびCD16に結合するタンパク質
US20210130471A1 (en) * 2017-02-20 2021-05-06 Dragonfly Therapeutics, Inc. Proteins binding cd33, nkg2d and cd16
KR20210029298A (ko) * 2017-08-16 2021-03-15 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
AU2018329937B2 (en) * 2017-09-07 2024-09-12 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and nectin4
PE20211224A1 (es) * 2018-02-20 2021-07-06 Dragonfly Therapeutics Inc Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
JP7353576B2 (ja) * 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス, インコーポレイテッド Cd33、nkg2d、及びcd16に結合する多重特異性結合タンパク質、ならびにその使用方法

Similar Documents

Publication Publication Date Title
JPWO2019231920A5 (enExample)
JP7487112B2 (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
Thakur et al. Cancer therapy with bispecific antibodies: Clinical experience
May et al. Advances in bispecific biotherapeutics for the treatment of cancer
Chen et al. Bispecific antibodies in cancer immunotherapy
JP2022169543A (ja) 改善された養子t細胞療法
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
IL312224B1 (en) Guidance and navigation control proteins and method of making and using thereof
JP2024519335A (ja) がん免疫療法のための投薬レジメン
Satta et al. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors
US20240218065A1 (en) Multispecific antigen-binding protein and use thereof
WO2023046156A1 (en) Il-2 variants and fusion proteins thereof
Dhimolea et al. World bispecific antibody summit, September 27–28, 2011, Boston, MA
IL301995A (en) Cells comprising t cell-antigen couplers and uses thereof
Kim et al. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
KR20240033025A (ko) Bcma-지시된 세포 면역요법 조성물 및 방법
CN117187185A (zh) 一种工程化免疫细胞及其用途
JPWO2019165116A5 (enExample)
CN114729305A (zh) 用于免疫治疗的嵌合抗原受体、制备方法及其应用
CN117004604A (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
Brandão et al. Bispecific Antibodies: An Emerging Concept in Antibody-Based Cancer Therapies
Mach Introduction to monoclonal antibodies
WO2025006631A1 (en) Dosing regimens for treatment of cancer
RU2024106065A (ru) Биспецифический рекомбинантный белок и его применение